Properties (82)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
strategic acquisitions
|
| gptkbp:businessModel |
research and development
strategic partnerships |
| gptkbp:CEO |
Steve_Harr
|
| gptkbp:clinicalTrials |
active
ongoing Phase 1 rare diseases multiple phases innovative therapies multiple sites extensive studies secured funding rigorous protocols promising outcomes |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:community |
improving patient outcomes
|
| gptkbp:communityEngagement |
outreach programs
|
| gptkbp:communityImpact |
positive contributions
|
| gptkbp:communityPartnerships |
collaborative efforts
|
| gptkbp:culturalHeritage |
innovation-driven
|
| gptkbp:employees |
over 100
|
| gptkbp:financialPerformance |
volatile
patents filed growing revenue |
| gptkbp:financials |
investor backing
|
| gptkbp:focus |
gene therapy
|
| gptkbp:founded |
2019
|
| gptkbp:founder |
Steve_Harr
|
| gptkbp:future_plans |
advanced cell therapies
|
| gptkbp:futurePlans |
expand into new therapies
|
| gptkbp:globalPresence |
international collaborations
|
| gptkbp:hasPrograms |
expert advisors
|
| gptkbp:hasResearchInterest |
in-depth analysis
|
| gptkbp:headquarters |
gptkb:Seattle,_Washington
|
| gptkbp:healthcare |
active involvement
focused on patient needs |
| gptkbp:historicalResearch |
joint ventures
groundbreaking studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Sana Biotechnology, Inc.
|
| gptkbp:investmentFocus |
over $300 million
various venture capital firms transparent communication |
| gptkbp:leadership |
diverse team
|
| gptkbp:leads |
top-tier venture capitalists
|
| gptkbp:market |
global market
adapting to changes planned launches |
| gptkbp:marketSegment |
strategic initiatives
targeted marketing |
| gptkbp:mission |
transform lives through cell and gene therapies
|
| gptkbp:partnerships |
biopharmaceutical companies
multiple pharmaceutical companies |
| gptkbp:productLine |
diverse candidates
|
| gptkbp:products |
cutting-edge technologies
|
| gptkbp:publicAccess |
2020
|
| gptkbp:regulatoryCompliance |
strict adherence
FDA_submissions |
| gptkbp:research |
significant funding rounds
|
| gptkbp:research_areas |
cardiology
metabolic disorders neurology oncology |
| gptkbp:researchAreas |
cell engineering
|
| gptkbp:researchFocus |
genetic diseases
|
| gptkbp:researchInterest |
academic partnerships
numerous publications awarded grants |
| gptkbp:riskManagement |
comprehensive strategies
|
| gptkbp:scientificName |
renowned scientists
|
| gptkbp:stockSymbol |
SANA
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:sustainabilityInitiatives |
environmental responsibility
|
| gptkbp:technology |
engineered cells
effective processes leading-edge solutions |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:training |
ongoing training programs
|
| gptkbp:tributaryOf |
multiple product candidates
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.sanabiotechnology.com
|